We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 149.27 | 0 | 01:00:00 |
From May 2019 to May 2024
By Chris Wack
Addex Therapeutics Ltd. said its partner, Janssen Pharmaceuticals Inc., has received the U.S. Food and Drug Administration's Investigational New Drug approval to begin a Phase 2a proof of concept study for a treatment for patients with epilepsy.
The clinical-stage pharmaceutical company said the first patient is expected to be treated during the second quarter of 2021.
Addex said the multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 administration in patients with focal onset seizures with suboptimal response to levetiracetam.
The primary objective of the study is to evaluate the efficacy of JNJ-40411813 in combination with levetiracetam using a time-to-event endpoint.
Addex Therapeutics shares were up 65% to $17.79 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 21, 2021 06:28 ET (11:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
